Search Within

Neeta Pandit-Taskar

  1. "2024"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (7)
  3. Review (3)
  4. Editorial (1)
Groups
  1. Molecular Imaging and Therapy Service (21)
  2. Radiology, Department of (21)
  3. Pediatrics, Department of (6)
  4. Graduate Medical Education (5)
  5. Medical Physics (5)
  6. Neuro-Oncology Service (5)

More Groups

People
  1. Brian Serencsits (4)
  2. Kim Kramer (4)
  3. Maria Donzelli (3)
  4. Serge Lyashchenko (3)
  5. Sofia Haque (3)
  6. Amitabh Srivastava (2)

More People

Years
  1. 2024 (21)
Publications
  1. Journal of Nuclear Medicine (7)
  2. Journal of Clinical Oncology (3)
  3. European Journal of Nuclear Medicine and Molecular Imaging (2)
  4. Seminars in Nuclear Medicine (2)
  5. Current Problems in Cancer (1)
  6. EJNMMI Research (1)

More Publications

Publishers
  1. Society of Nuclear Medicine (7)
  2. American Society of Clinical Oncology (3)
  3. Elsevier Inc. (3)
  4. Springer (3)
  5. Elsevier Science, Inc. (1)
  6. Mosby Elsevier (1)

More Publishers

Results (21)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 dose finding study evaluating the safety, tolerability, and efficacy of iopofosine I 131 in children, adolescents, and young adults with inoperable relapsed or refractory high-grade gliomas: A trial-in-progress
    Meeting Abstract

    Sait, S. F.; Morgenstern, D. A.; Pandit-Taskar, N.; Das, A.; Pudel, M.; Fisher, C.; Zanzonico, P.; Haque, S.; Longcor, J.; Shustov, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Survival outcomes and dosimetric analysis of Iomab-B (131I-apamistamab) followed by allogeneic hematopoietic cell transplant for patients with TP53 mutated relapsed/refractory AML
    Meeting Abstract

    Natwa, M.; Leung, E.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Wahl, R.; Avril, N.; Lamonica, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Exploratory analysis of bone marrow dosimetry from the randomized phase 3 SIERRA trial of Iomab-B (131I-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia
    Meeting Abstract

    Pandit-Taskar, N.; Natwa, M.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Passalaqua, S.; Avril, N.; Lamonica, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Computational nuclear oncology for precision radiopharmaceutical therapies
    Meeting Abstract

    Yusufaly, T.; Roncali, E.; Uribe, C.; Shi, K. Y.; Bradshaw, T.; Jha, A.; Strigari, L.; Currie, G.; McMeekin, H.; Schwartz, J.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Mathematical modeling of exposure measurements following high-dose targeted therapy using 131I-apamistamab: Analysis from the large multicenter phase III SIERRA trial
    Meeting Abstract

    Pandit-Taskar, N.; Chen, L. Y.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Bone marrow dosimetry exploratory analysis from the phase 3 SIERRA trial of (131)I-apamistamab prior to HCT in relapsed/refractory acute myeloid leukemia
    Meeting Abstract

    Pandit-Taskar, N.; Natwa, M.; Chen, M.; Leung, E.; Spross, J.; Li, K.; Desai, A.; Brodin, P.; Wahl, R.
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Modeling-based assessment of exposure measurements after high-dose targeted (131)I-apamistamab: Results and analyses from the phase III SIERRA trial
    Meeting Abstract

    Pandit-Taskar, N.; Chen, L.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
    European Journal of Nuclear Medicine and Molecular Imaging (2024)

    Fulltext@MSK | Save
  • Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes
    Journal Article

    Sait, S. F.; Kernan, N. A.; Klein, E.; Spitzer, B.; Levy, C. F.; Fish, J.; Yildirim, O.; Haque, S.; Donzelli, M.; Bernot, M. R.; more...
    Pediatric Blood and Cancer (2024)

    Fulltext@MSK | Save
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • [(89)Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: A prospective, open-label, multicentre, phase 3 trial
    Journal Article

    Shuch, B.; Pantuck, A. J.; Bernhard, J. C.; Morris, M. A.; Master, V.; Scott, A. M.; van Praet, C.; Bailly, C.; Önal, B.; Aksoy, T.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save